Monuscript title which is presenting sequencing data obtained through the Silent Genomes Project and/or using the genomic data within the IBVL for the analysis and/or Please describe how the Silent Genomes varient information was used. 100 word limit We have reviewed the Silent Genomes IBVL Resource document. We confirm that, to the best of our knowledge, this manuscript is presenting genomic data in a way that □ reduces the chance of its secondary use, □ and protects confidentiality and privacy of participating individuals, families and communities □ This manuscript has been created in an active partnership with Indigenous patients,	•	Ver 3, May 1
Date: Author Name(s): Institution(s): (please include community affiliation) We are submitting for your review the manuscript titled:	•	
Institution(s): Institution(s): (please include community affiliation) We are submitting for your review the manuscript titled: Munuscript title	•	Re: Request for Manuscript Review
Institution(s): (please include community affiliation) We are submitting for your review the manuscript titled:		Date:
We are submitting for your review the manuscript titled: Manuscript title which is presenting sequencing data obtained through the Silent Genomes Project and/or using the genomic data within the IBVL for the analysis and/or We have reviewed the Silent Genomes IBVL Resource document. We confirm that, to the best of our knowledge, this manuscript is presenting genomic data in a way that reduces the chance of its secondary use, and protects confidentiality and privacy of participating individuals, families and communities This manuscript has been created in an active partnership with Indigenous patients, families, communities and their designated organizations which allowed them to review and/or contribute to the:	Au	thor Name(s):
We are submitting for your review the manuscript titled: Monuscript title which is presenting sequencing data obtained through the Silent Genomes Project and/or using the genomic data within the IBVL for the analysis and/or We have reviewed the Silent Genomes IBVL Resource document. We confirm that, to the best of our knowledge, this manuscript is presenting genomic data in a way that reduces the chance of its secondary use, and protects confidentiality and privacy of participating individuals, families and communities This manuscript has been created in an active partnership with Indigenous patients, families, communities and their designated organizations which allowed them to review and/or contribute to the:	In	stitution(s):
□ which is presenting sequencing data obtained through the Silent Genomes Project and/or □ using the genomic data within the IBVL for the analysis and/or Please describe how the Silent Genomes variant information was used. 100 word limit □ We have reviewed the Silent Genomes IBVL Resource document. We confirm that, to the best of our knowledge, this manuscript is presenting genomic data in a way that □ reduces the chance of its secondary use, □ and protects confidentiality and privacy of participating individuals, families and communities □ This manuscript has been created in an active partnership with Indigenous patients, families, communities and their designated organizations which allowed them to review and/or contribute to the:	We	
Please describe how the Silent Genomes variant information was used. 100 word limit We have reviewed the Silent Genomes IBVL Resource document. We confirm that, to the best of our knowledge, this manuscript is presenting genomic data in a way that reduces the chance of its secondary use, and protects confidentiality and privacy of participating individuals, families and communities This manuscript has been created in an active partnership with Indigenous patients, families, communities and their designated organizations which allowed them to review and/or contribute to the:		which is presenting sequencing data obtained through the Silent Genomes Project
 We have reviewed the <u>Silent Genomes IBVL Resource document</u>. We confirm that, to the best of our knowledge, this manuscript is presenting genomic data in a way that □ reduces the chance of its secondary use, □ and protects confidentiality and privacy of participating individuals, families and communities □ This manuscript has been created in an active partnership with Indigenous patients, families, communities and their designated organizations which allowed them to review and/or contribute to the: 	an	·
 We have reviewed the <u>Silent Genomes IBVL Resource document</u>. We confirm that, to the best of our knowledge, this manuscript is presenting genomic data in a way that □ reduces the chance of its secondary use, □ and protects confidentiality and privacy of participating individuals, families and communities □ This manuscript has been created in an active partnership with Indigenous patients, families, communities and their designated organizations which allowed them to review and/or contribute to the:		
 We have reviewed the <u>Silent Genomes IBVL Resource document</u>. We confirm that, to the best of our knowledge, this manuscript is presenting genomic data in a way that □ reduces the chance of its secondary use, □ and protects confidentiality and privacy of participating individuals, families and communities □ This manuscript has been created in an active partnership with Indigenous patients, families, communities and their designated organizations which allowed them to review and/or contribute to the:		
We confirm that, to the best of our knowledge, this manuscript is presenting genomic data in a way that reduces the chance of its secondary use, and protects confidentiality and privacy of participating individuals, families and communities This manuscript has been created in an active partnership with Indigenous patients, families, communities and their designated organizations which allowed them to review and/or contribute to the:	Ple	ase describe how the Silent Genomes variant information was used. 100 word limit
a way that ☐ reduces the chance of its secondary use, ☐ and protects confidentiality and privacy of participating individuals, families and communities ☐ This manuscript has been created in an active partnership with Indigenous patients, families, communities and their designated organizations which allowed them to review and/or contribute to the:		We have reviewed the Silent Genomes IBVL Resource document.
and protects confidentiality and privacy of participating individuals, families and communities This manuscript has been created in an active partnership with Indigenous patients, families, communities and their designated organizations which allowed them to review and/or contribute to the:		, , , , , , , , , , , , , , , , , , , ,
communities This manuscript has been created in an active partnership with Indigenous patients, families, communities and their designated organizations which allowed them to review and/or contribute to the:		\square reduces the chance of its secondary use,
families, communities and their designated organizations which allowed them to review and/or contribute to the:		
		milies, communities and their designated organizations which allowed them to review d/or contribute to the:
· ·		

Please describe in which way. If no partnership, please describe why. 100 word limit

Consents are in place, copies are attached. Yes / No / Not applicable	
If no consents in place or no consents attached please describe why. 100 word limit	
We are aware that additional approved review(s) may be required by partici communities, the Alliance for Healthy Hearts and Minds, or Indigenous organization(s)	-
A manuscript is attached (if attached, it will remain confidential)	
☐ The lay summary is provided below	
Lay summary, 250 word limit. In the author's own words, please write for a lay audience	
The best way to contact the corresponding author is by:	
Email or phone number	
Additional infirmation:	
Anything else authors would like to share	
Sincerely,	
Email: Email:	
Email:	
Email: Email:	
Email:	
Email: Email:	

We have indicated above with a * those email addresses of approved IBVL users.